1-5 of 5
John Radford
Close
Sort by
Journal Articles

Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial

Clinical Trials & Observations
Mehdi Hamadani, Alexander Spira, Xiaolei Zhou, Laura Liao, Lei Chen, John Radford, Weiyun Ai, Melhem Solh, Kirit M. Ardeshna, Brian Hess, Paolo F. Caimi, Anastasios Stathis, Carmelo Carlo-Stella, Juan Pablo Alderuccio, Brad Kahl, Ying Wang, Yajuan Qin, Zhiying Cindy Xu, Pier Luigi Zinzani
Journal: Blood Advances
Blood Adv (2023) 8 (1): 93–98.
https://doi.org/10.1182/bloodadvances.2023010636
Published: 2023
Includes: Supplemental data
Journal Articles

The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network

Greg Hapgood, Monica Civallero, Yana Stepanishyna, Julie Vose, Monica Elena Cabrera, Ranjana H. Advani, Stefano A. Pileri, Martina Manni, Steven M. Horwitz, Francine M. Foss, Felicitas Hitz, John Radford, Ivan Dlouhy, Carlos Chiattone, Won Seog Kim, Tetiana Skrypets, Arnon Nagler, Judith Trotman, Stefano Luminari, Massimo Federico
Journal: Blood Advances
Blood Adv (2023) 7 (17): 5047–5054.
https://doi.org/10.1182/bloodadvances.2023010037
Published: 2023
Includes: Supplemental data
Journal Articles

Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study

Clinical Trials & Observations
Juan P. Alderuccio, Weiyun Z. Ai, John Radford, Melhem Solh, Kirit M. Ardeshna, Matthew A. Lunning, Brian T. Hess, Pier L. Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S. Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F. Caimi
Journal: Blood Advances
Blood Adv (2022) 6 (16): 4736–4739.
https://doi.org/10.1182/bloodadvances.2022007782
Published: 2022
Journal Articles

Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial

Clinical Trials & Observations
Alex F. Herrera, Catherine Burton, John Radford, Fiona Miall, William Townsend, Armando Santoro, Pier Luigi Zinzani, David Lewis, Camilla Fowst, Satjit Brar, Bo Huang, Aron Thall, Graham P. Collins
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3387–3396.
https://doi.org/10.1182/bloodadvances.2021004511
Published: 2021
Includes: Supplemental data
Journal Articles

Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma

Clinical Trials & Observations
Tim M. Illidge, Elizabeth H. Phillips, Nicholas Counsell, Ruth Pettengell, Peter W. M. Johnson, Dominic J. Culligan, Bilyana Popova, Laura Clifton-Hadley, Andrew McMillan, Peter Hoskin, Sally F. Barrington, John Radford
Journal: Blood Advances
Blood Adv (2020) 4 (1): 203–206.
https://doi.org/10.1182/bloodadvances.2019001023
Published: 2020
Includes: Supplemental data